SignaBlok

SignaBlok is a private, preclinical-stage biotech developing a new class of peptide drugs and targeted nanosystems based on its foundational SCHOOL platform for cell receptor signaling. The company's approach, inspired by viral evasion mechanisms, aims to disrupt pathological immune responses by modulating macrophage activity in a range of serious inflammatory and immune diseases. Led by its founder and CEO, Dr. Alexander B. Sigalov, the firm is built on a strong IP portfolio and academic research but operates as a pre-revenue entity with an undisclosed pipeline stage and financial backing.

SCHOOL (Signaling Chain HOmoOLigomerization) model for receptor signaling, enabling design of ligand-independent inhibitory/modulatory peptides. Platform also includes multifunctional nanosystems for targeted drug/imaging agent delivery to inflammation sites.

The field of macrophage modulation and targeted anti-inflammatory therapies is highly competitive, with numerous large biopharma and biotech companies pursuing cytokine inhibitors, cell therapies, and other modalities. SignaBlok's platform is scientifically distinct but will need to demonstrate clear advantages over established and emerging therapies to secure funding and partnerships.